IMTX
Immatics N.V. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 2,
"returned": 2,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "b29422a8-42b7-4fba-a67b-5927b67e4563",
"title": "Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates",
"description": "Immatics (IMTX) delivered earnings and revenue surprises of 94.59% and 85.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?",
"keywords": "stock, stocks, investment, investment advice, investing, online trading, online investment, online stock trading, stock market, financial, financial planning, quote, quotes, stock quotes",
"snippet": "This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...",
"url": "https://www.zacks.com/stock/news/2273289/immatics-imtx-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2273289",
"image_url": "https://staticx-tuner.zacks.com/images/default_article_images/default171.jpg",
"language": "en",
"published_at": "2024-05-14T12:15:03.000000Z",
"source": "zacks.com",
"relevance_score": null,
"entities": [
{
"symbol": "IMTX",
"name": "Immatics N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 51.973145,
"sentiment_score": 0.25,
"highlights": [
{
"highlight": "<em>Immatics</em> (IMTX) Reports Q1 Loss, Tops Revenue Estimates",
"sentiment": 0.25,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "3ed8eb1b-5cb3-47a0-b2f2-f8dbe2f712d5",
"title": "Immatics Announces First Quarter 2024 Financial Results and Business Update",
"description": "Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on...",
"keywords": "Nasdaq:IMTX, Immatics N.V., Immatics N.V., IMTX, Cell Therapy, Immunooncology, Immunotherapy, TCR-Therapeutics, Quarterly report",
"snippet": "Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with\n\nACTengine® IMA203 TCR-T Targeting PRAME\n\nUpdated clinical data on ACTengine® I...",
"url": "https://www.globenewswire.com/news-release/2024/05/14/2881232/0/en/Immatics-Announces-First-Quarter-2024-Financial-Results-and-Business-Update.html",
"image_url": "https://ml-eu.globenewswire.com/Resource/Download/1ef1cd0c-384c-4889-82c8-58bd42054fb8",
"language": "en",
"published_at": "2024-05-14T11:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "IMTX",
"name": "Immatics N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 74.577614,
"sentiment_score": -0.001691,
"highlights": [
{
"highlight": "<em>N.V</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ</em>: <em>IMTX</em>, “<em>Immatics</em>”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2024.",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "For IMA203CD8 (GEN2), <em>Immatics</em> cleared dose level 4a (DL4a, up to ~1.6x109 TCR-T cells) in December 2023. <em>Immatics</em> plans to continue dose escalation with the goal to define the optimal dose for further development.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Immatics</em>\n\n<em>Immatics</em> combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "For more information, please contact:\n\nMedia Trophic Communications Phone: +49 171 3512733 <em>immatics</em>@trophic.eu\n\n\n\n\n\n<em>Immatics</em> <em>N.V</em>. Jordan Silverstein Head of Strategy Phone: +1 346 319-3325 [email protected]\n\n<em>Immatics</em> <em>N.V</em>. and subsidiaries\n\nCondensed Consolidated Statement of Loss of <em>Immatics</em> <em>N.V</em>.",
"sentiment": 0.0717,
"highlighted_in": "main_text"
},
{
"highlight": "<em>N.V</em>. and subsidiaries\n\nCondensed Consolidated Statement of Comprehensive Loss of <em>Immatics</em> <em>N.V</em>.",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Three months ended March 31,\n\n\n\n2024\n\n\n\n2023\n\n\n\n(Euros in thousands) Net loss (3,054) (19,747) Other comprehensive income Items that may be reclassified subsequently to profit or loss Currency translation differences from foreign operations 336 564 Total comprehensive loss for the year (2,718) (19,183)\n\n<em>Immatics</em> <em>N.V</em>. and subsidiaries\n\nCondensed Consolidated",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Statement of Financial Position of <em>Immatics</em> <em>N.V</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>N.V</em>. and subsidiaries\n\nCondensed Consolidated Statement of Cash Flows of <em>Immatics</em> <em>N.V</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>N.V</em>. and subsidiaries\n\nCondensed Consolidated Statement of Changes in Shareholders’ equity of <em>Immatics</em> <em>N.V</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Immatics</em> Announces First Quarter 2024 Financial Results and Business Update",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "IMTX",
"total_documents": 2,
"sentiment_avg": 0.12415450002299622
}
]
}
Other details
Exchange
- NASDAQ Stock Exchange
- equity
- Healthcare
- us